|Bid||78.00 x 900|
|Ask||78.03 x 900|
|Day's Range||76.83 - 78.76|
|52 Week Range||68.25 - 131.95|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||17.10|
|Earnings Date||Feb 24, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||108.24|
NEW YORK, NY / ACCESSWIRE / November 24, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies.
NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc.
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.